• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Pharma

Eli Lilly Takes Legal Action Against Telehealth Startups

byDeepti Shroff Karhade
May 15, 2025
in Pharma
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter
Key Points:
1. Lilly sues four telehealth firms for unauthorized compounding of Mounjaro and Zepbound.
2. GLP 1 drugs remain in high demand as scrutiny of telehealth practices intensifies.

Eli Lilly has filed lawsuits against four digital health companies that it claims are distributing unauthorized compounded versions of its blockbuster medications Mounjaro and Zepbound. These drugs are widely used to treat diabetes and obesity and together brought in more than 16 billion dollars for Lilly last year. The lawsuits name Mochi Health, Fella and Delilah Health, Willow Health, and Henry Meds as the defendants. According to Lilly, these companies are selling formulations that include unapproved additives like vitamins and amino acids in an effort to differentiate their products from the original medications. Lilly alleges that these compounded drugs are not only untested but also being produced in bulk, rather than in response to individual prescriptions, which violates federal compounding rules. The Food and Drug Administration (FDA) had previously declared that shortages of Mounjaro and Zepbound had been resolved, eliminating one of the main legal justifications for compounding these drugs. Nevertheless, some telehealth startups have continued to market compounded versions, prompting legal action. The lawsuits bring to light the growing friction between pharmaceutical manufacturers and the rapidly expanding telehealth sector. As patients increasingly seek online alternatives for care, questions around regulation, safety, and quality control have become more urgent. Regulatory agencies have started cracking down on unlicensed compounding operations, some of which have already been forced to shut down. Lilly’s legal campaign could set an important precedent that reshapes how compounded drugs are governed in the digital age. It also underscores the importance of ensuring patient safety in a space that is evolving faster than policy can keep up.

Relevant reading:
GLP-1 Drug Compounding Sparks FDA Scrutiny and Lawsuits
©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

FDA Approves Dupilumab for Chronic Spontaneous Urticaria

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

2 Minute Medicine: AI Roundup [May 2nd, 2025]

Tags: diabetesdrugsglp-1obesityPharmatelehealthZepbound
Previous Post

Both intestinal ultrasound and magnetic resonance imaging can assess radiologic stricturing in Crohn’s disease

RelatedReports

Combined immunotherapy may improve survival in metastatic pancreatic cancer
Pharma

FDA Approves Dupilumab for Chronic Spontaneous Urticaria

May 14, 2025
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

May 12, 2025
2 Minute Medicine: AI Roundup [May 2nd, 2025]
AI Roundup

2 Minute Medicine: AI Roundup [May 2nd, 2025]

May 2, 2025
Intrapartum serum prolactin may predict risk of postpartum diabetes
Cardiology

Utilization of an early-life risk factor score to determine later life type 2 diabetes risk

April 29, 2025

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Eli Lilly Takes Legal Action Against Telehealth Startups
  • Both intestinal ultrasound and magnetic resonance imaging can assess radiologic stricturing in Crohn’s disease
  • FDA Approves Dupilumab for Chronic Spontaneous Urticaria
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.